Gainers

• Crinetics Pharmaceuticals (NASDAQ:CRNX) shares moved upwards by 98.7% to $83.53 during Tuesday's regular session. The company's market cap stands at $4.4 billion.
• Tvardi Therapeutics (NASDAQ:TVRD) stock moved upwards by 40.04% to $2.81. The company's market cap stands at $18.8 million.
• Akari Therapeutics (NASDAQ:AKTX) shares increased by 32.75% to $14.47. The company's market cap stands at $19.0 million.
• Bluejay Diagnostics (NASDAQ:BJDX) stock moved upwards by 31.03% to $1.52. The market value of their outstanding shares is at $1.2 million.
• Veraxa Biotech Holding (NASDAQ:VRXA) shares moved upwards by 21.0% to $2.65. The company's market cap stands at $309.6 million.
• Pyxis Oncology (NASDAQ:PYXS) shares increased by 19.71% to $2.94. The market value of their outstanding shares is at $155.8 million.

Losers

• Basel Medical Group (NASDAQ:BMGL) shares fell 15.2% to $5.97 during Tuesday's regular session. The company's market cap stands at $11.0 million.
• YD Bio (NASDAQ:YDES) stock declined by 14.96% to $1.99. The market value of their outstanding shares is at $165.7 million.
• Conexeu Sciences (NASDAQ:CNXU) shares decreased by 14.26% to $9.26. The market value of their outstanding shares is at $288.9 million.
• Axe Compute (NASDAQ:AGPU) shares fell 12.49% to $7.36. The company's market cap stands at $95.7 million.
• CollPlant Biotechnologies (NASDAQ:CLGN) stock declined by 12.33% to $0.38. The market value of their outstanding shares is at $5.4 million.
• Forum Markets (NASDAQ:FRMM) shares fell 12.05% to $5.99. The company's market cap stands at $89.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.